Palatin, AstraZeneca PhI obesity trial halted on "serious" AE
This article was originally published in Scrip
Executive Summary
Palatin Technologies said a Phase I trial being conducted by AstraZeneca of AZD2820, a subcutaneously administered peptide melanocortin-4 receptor partial agonist under development as a potential anti-obesity agent, has been halted after a man enrolled in the study had a serious adverse event.